Mitral Butterfly is a proprietary chordal repair technique restoring the coaptation plane of a flail leaflet in degenerative mitral regurgitation. Additionally, the unique deployment technique restores the support apparatus of the mitral valve in one step. It is an unparalleled technique and a differentiated method from presently known repair concepts. The primary advantage of the mechanism of action containing the prolapsing segment is the introduction of an artificial papillary muscle as valvular support.

The Mitral Butterfly device is intended to advance chordal repair. The present chronic animal study was to demonstrate safety of the device at 90-day follow-up. There were no device related adverse effects and no deterioration of valve function during follow up. All safety endpoints were met, and structural integrity was maintained out to an average of 12 million cycles per animal.

Patrick Maguire MD, MBA, said: “the successful completion of the chronic animal study is a major step in the development of a feasible mitral repair system and an advancement of mitral innovation”. Werner Mohl, MD, PhD, Founder of AVVie added: “we are pleased to reach this important milestone in line with our ambitious development plan. We are committed to bring a safe and effective device to the clinical arena.

AVVie GmbH has been announced as the start-up track winner in the category MedTech in the Best of Biotech (BoB) 2019 Ceremony Awards.
BoB – Best of Biotech is an international life science businessplan competition recognizing life science innovations and honoring scientists. The BoB award program gives innovators a chance to stand out in the life science community and motivates them to become entrepreneurs. The aim of BoB is to promote Austria and Central Europe as a life science business incubator, active in the pharmaceutical, biotech and medtech fields.

On 23rd of October 2019 the Austrian Federal Ministry for Digital and Economic Affairs and Austria Wirtschaftsservice announced the award winners at the aws Bob – Best of Biotech: Award Ceremony (httpss://www.bestofbiotech.at/winners/), the prestigious gathering of the best early phase pitches and the best start up projects in each of the following categories: biotech/pharma, medtech and digital health. Finalists were selected by a group of experienced judges and, from the group of finalists, one winner from each category was awarded.

AVVie GmbH was announced as the winner of the first edition of Innovasc organized by iVascular. iVascular is a company dedicated to the development, commercialization and manufacture of technologically advanced medical devices and treatment methods for different vascular diseases.

For more information see:
httpss://ivascular.global/ivasculars-first-open-innovation-initiative-innovasc-is-pleased-to-announce-the-winner-of-the-grant/

“Mitral Butterfly” will be presented in one of the most prestigious meetings for structural heart innovations worldwide.

Moreover, the abstract „Mitral Butterfly: Evaluation of a novel device in porcine and human hearts“ has been accepted and will be presented at the TVT Moderated Poster Session.
It is a great scientific success and a unique opportunity to be a part of such a clinically-relevant conference in structural heart disease.

It is an honour to be actively involved in the innovation session of the TVT Structural Heart Summit in Chicago this year.

AVVie GmbH won the Austrian Founder Award Phoenix 2018 in the category “Prototype”. This award validates prototype projects in basic research and development co-financed through public grants by the Austrian Research Promotion Agency (Österreichische Forschungsförderungsgesellschaft mbH, FFG) and the Austria Wirtschaftsservice Gesellschaft mbH (aws).

A distinguished jury selected AVVie as a Phoenix laureate and the award was presented jointly by the Austrian Minister of Digital and Economic Affairs and the Austrian Minister of Education, Science and Research during a prize ceremony on December 3^rd 2018 in Vienna.